• 384細胞同時測定
• 32ウェルモードにより小規模な化合物スクリーニングや研究プロジェクトにも最適化
• 高いギガシール成功率
• 高速外部溶液交換（最大110 µl/s）が可能
• 記録中の内部溶液の灌流が可能（例：細胞内カルシウム依存性のK⁺チャネルの記録が可能）
• 測定部と12個のデッキを個別に温度コントロール可能（温度範囲：10～37℃）
• カレントクランプによる活動電位の測定も可能
• シングル & マルチホールチップを使用可能（自社製造）
• プログラムの自動化により、約８時間の無人運転が可能
• 濃度解析のために測定後の溶液を回収することが可能
• 優れたサービスとサポートを提供します

• ナニオンのパッチクランプチップは、マニュアルパッチクランプで使用されるガラスキャピラリーと同様にホウケイ酸ガラス製のため、低キャパシタンス、低化合物吸着、優れたパッチ／シール特性を実現しています
• オンデッキでの化合物プレートの準備 - 化合物の準備のために別の自動分注機を使用したり、手作業で化合物プレートを準備する必要はありません。
• 流路タイプのチップと比較して、溶液と壁面の接地面積が低いため、化合物の吸着が低い
• 化合物暴露 & wash回数の制限なし
• グリッパーとピペッティングヘッドが独立して稼働するため、例えば化合物の蓋を外す際にピペッティングチップを外す必要がありません
• 少量の化合物で実験が可能
• 強力な解析ソフトウェア（フレキシブルなバッチ解析、IC₅₀計算、IV解析、Genedata Screenerとの互換性あり）
• z-primeとヒートマップにより、データの概要を迅速かつ視覚的に把握することが可能
• 設定、編集、分析が簡単にできます
• スタンダードとアドバンスの異なる操作モードにより、実験パラメータの柔軟性を維持しながら、シンプルに操作できます
• スループットの選択 - 32ウェルモードでは、実験に適したスループットを常に選択できます

• 電位依存性 & リガンド依存性チャネルに対応
• 少ない細胞量で実験が可能 – 幹細胞や初代細胞にも適用可能
• 様々なイオンチャネルに適用可能
• CiPA validation studyにおいて様々なデータを提供
• 創薬のあらゆるフェーズに対応
• データを様々なフォーマットでエクスポートし、外部ツールで簡単に解析可能
• 様々なCROアッセイに対応できる柔軟性

The SyncroPatch 384 includes:

• Biomek i5 with a 384-pipettor arm, gripper and temperature-controlled deck positions
• Temperature-controlled patch clamp module
• Amplifier (384 channels) incl. current clamp
• Windows 10 OS with PatchControl 384 and DataControl 384 software suite
• Guided Labware Setup and Method Launcher
• Temperature-controlled cell hotel
• Barcode scanner
• NPC-384 borosilicate recording chips
• Optional service plans for unmatched

SyncroPatch 384 data and applications:
Cells were kindly provided by SB Drug Discovery

An exemplary 32-well Mode Experiment. A small fraction of the chip can be used at a time, which is ideal for smaller compound screens.
Consecutive experiments of 32-wells on the same NPC-384 patch clamp chip over multiple days. Success rate and accurate pharmacology remains stable over 8 days as shown in the figure. Nav1.5 recordings in the presence of increasing Mexiletine concentrations.

SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
Cells were kindly provided by SB Drug Discovery.

The AMPA receptor (GluA2) was activated using different concentrations of glutamate (1 µM - 100 µM). Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384), the whole cell patch methodology and multi-hole chips were used.
The lower two images are displaying screenshots of single cell currents after repetitive glutamate applications:
Left: The same concentration of Glutamate was applied three times.
Right: Four different Glutamate concentrations were applied in a cumulative manner.

SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
Cells were kindly provided by SB Drug Discovery.

The AMPA receptor (GluA2)was activated by increasing concentrations of glutamate on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). L-glutamate was applied for approximately 500 ms in increasing concentrations (A) and a cumulative concentration response curve for glutamate was constructed for 222 wells (C).
The online analysis values peak amplitude and area under the curve (AUC) are shown versus time in Panel B. The fast activation of GluA2 could be captured at higher concentrations (inset; 1 mM).

SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
Cells were kindly provided by SB Drug Discovery.

The AMPA receptor (GluA2) was analyzed using different positive and negative allosteric modulators (CNQX, LY404187, LY395153, CP465022, Cyclothiazide). After activating the receptor by application of Glutamate, the modulating compound plus glutamate was applied afterwards. Measured on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384), the whole cell patch methodology and multi-hole chips were used.
The lower images on the left hand side are displaying a screenshot of a current after application of the positive modulator LY404187. The EC₅₀ was determined as 379 nM.

CardioExcyte 96 and SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
Cells were kindly provided by Charles River and Cellular Dynamics.

The image on the left hand side displays the results of the blocking effect of Sotalol on hERG. The result is in good agreement with manual patch clamp data (Crumb et al., 2016). The compound induced arrhythmia when iPSC-CM were exposed to a minimum concentration of 10 µM. Arrhytmic events were both detected in field potential recordings as well as in the impedance based contractility measurements.

SyncroPatch 384PE (a predecessor model of SyncroPatch 384) data and applications:
Cells kindly provided by Charles River.

Ca_V1.2 expressed in CHO cells recorded on the SyncroPatch 384PE (a predecessor model of SyncroPatch 384). A The screenshot shows the data acquisition and analysis software used on the SyncroPatch 384PE. The online analysis values are shown for a current-voltage experiment. B The raw traces from an example cell elicited by depolarizing steps from -60 mV to 40 mV in 10 mV increments from a holding potential of -80 mV are shown. C The normalized current-voltage plot for an average of 272 cells. A Boltzmann equation fit revealed a V_0.5 of activation of -4.8 mV.

SyncroPatch 384i (a predecessor model of SyncroPatch 384) data and applications:
Cells were kindly provided by Charles River.

Activation of hClC-1 tail currents expressed in CHO cells recorded on the SyncroPatch 384i (a predecessor model of SyncroPatch 384). A pre-pulse voltage step to +60 mV was followed by voltage steps from -120 mV to +80 mV for 300 ms (increasing in 20 mV steps) and the tail current was measured at the subsequent step to -100 mV. Out of a possible 384 wells, all 384 wells were used for the IV analysis

SyncroPatch 384i (a predecessor model of SyncroPatch 384) data and applications:
Cells were kindly provided by Charles River.

Tail currents of ClC-1 expressed in CHO cells were inhibited by increasing concentration of 9-AC. A single concentration of 9-AC was added to each well and the concentration response curve constructed over multiple wells. The IC₅₀ was calculated to be 6.3 µM for an average of 352 wells. The average current traces are also shown.

SyncroPatch 384 data and applications:
Cells were kindly provided by SB Drug Discovery

The AMPA receptor (GluA2) was activated using increasing concentrations of glutamate. Measured on the SyncroPatch 384 the whole cell patch methodology and multi-hole chips were used. The faster you apply the ligand, the shorter is the Time to Peak, this means pipetting speed is relevant for accurate pharmacology. The IC₅₀ of Glutamate at 110 µl/s was 460 µM.

Piezo1 channels endogenously expressed in Neuro2A cells were investigated on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384). A Screenshot of the PatchControl 384 software during an experiment. B Statistical analysis of the currents at -100mV (left) and at 80 mV (right). 140 out of 384 Neuro2A cells (37%) passed the quality criteria and 85 cells (60% of the valid cells) were considered as Yoda1 responders.

Data from Rotordam et al, 2019.

Current response of Piezo1 activated by Yoda1 in patient cells with the novel PIEZO1 mutation (R2110W) compared to healthy red blood cells (RBCs). Shown are raw data traces (top) and statistical analysis of all measured cells, independent of their response to Yoda1 (bottom).

Data from Rotordam et al, 2019.

Whole-cell recordings of ion currents from RBCs of healthy donors and Hereditary Xerocytosis patients. Different mutations in the PIEZO1 gene were compared with controls. Aa The P50.2 mutation resulted in current conductance that was unchanged compared with transport controls, but showed increased conductance compared with general controls (Ab). The mutation P52.1 showed decreased conductance compared with transportation controls (Ba) and general controls (Bb).

Data from Petkova-Kirova et al, 2019.

“We are extraordinarily excited about installing the first SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) in an academic setting in North America. The enormous throughput, intuitive software and robust liquid handling capabilities along with superior seal quality, stability and high success rates convinced us to purchase the instrument. The SyncroPatch 384PE will enable us to perform detailed high throughput analysis of genetic variants in human ion channels at a previously unobtainable scale, and will form the cornerstone of a new HTS facility we are building. We also look forward to upgrading to 768 wells in the near future.“

Dr. Al George
Professor and Chair of Pharmacology at Northwestern University Feinberg School of Medicine, Chicago, IL, USA

“I measured CRCs for activation and steady-state desensitization, as well as peptide modulation of the channel, and got fantastic support from Søren Friis both with technical questions and assay design .The SyncroPatch and its software are easy to use and allow for versatile assay design. The team at Nanion goes out of their way to help with all questions and requests that come up, and they host fantastic user meetings for idea exchange. After four years using the SyncroPatch, I can highly recommend it.”“

Nina Braun 
University of Copenhagen

Basic principles of external solution exchange and compound addition

Speakers:Dr. Alison Obergrussberger (Nanion Technologies)

This is an on-demand webinar from Nan]i[on and Friends 2020.

The SyncroPatch 384i – is a giga-ohm seal HTS automated patch clamp platform based on the newly introduced and state-of-the art Biomek i5 liquid handler.

It provides effortless ion channel screening coupled with unmatched flexibility, ease-of-use and reliability. The SyncroPatch 384i builds on the success of the SyncroPatch 384PE, which has been globally established as the preferred automated patch clamp workhorse in Pharma, Biotech, CRO and academia.